Guideline for the Funding of Projects on the Topic of Transnational Research Projects within the European Partnership One Health Antimicrobial Resistance on Combination Therapies and Therapy Adherence

Within the framework of the European Partnership One Health Antimicrobial Resistance (EUP OHAMR), the directive supports transnational research collaborations between public institutions and companies within the EU that jointly develop novel combination therapies against antibiotic- and antifungal-resistant pathogens, as well as analyze and improve barriers to therapy adherence. With a duration of up to 11 months, the measure aims to combat antibiotic resistance efficiently and ensure the clinical efficacy of antimicrobial treatments. As a project outline, interested parties must submit electronically via the PT-Outline portal by February 2, 2026, and transmit it through a transnational consortium coordinator to the Joint Call Secretariat at ANR. Only fully registered consortia may later submit a full application upon request (deadline: June 17, 2026). Eligible expenses include personnel, material costs, and necessary travel, while selection is based on innovation content, scientific excellence, and the degree of international collaboration.

The funding strengthens the EU-wide research infrastructure by bringing together interdisciplinary teams and promoting joint knowledge transfer between science and industry. With a One Health perspective, humans, animals, and the environment are considered integratively to sustainably contain resistance. Precisely defined evaluation criteria ensure that projects are both innovative and practice-oriented. The financial resources are provided as a non-repayable grant and contribute to publishing or protecting results at the end of the project duration. Research actors thus have the opportunity to develop transnational solutions for this global health challenge and facilitate patients' access to more effective therapies.